Dr. Reddy’s Laboratories gets Health Canada nod for generic Semaglutide injection
Dr. Reddy’s Laboratories has received approval from Health Canada for its generic Semaglutide Injection, becoming the first company to do so in Canada. This approval covers both the 2 mg and 4 mg pen formulations of the drug, which is used to treat Type 2 diabetes. The company aims to provide an important treatment option for the approximately 3.9 million Canadians diagnosed with diabetes.
- ▪Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection.
- ▪The approval includes 2 mg and 4 mg pen formulations of the drug.
- ▪Canada is the second-largest market for Semaglutide, with around 3.9 million people diagnosed with diabetes.
The Hindu — Top publishes from India and files mainly under world. We currently carry 7,904 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Hindu — Top |
| Canonical URL | https://www.thehindu.com/business/Industry/dr-reddys-laboratories-gets-health-canada-nod-for-generic-semaglutide-injection/article70919311.ece |
| Publication time | Wed, 29 Apr 2026 12:48:52 +0530 |
| Retrieval time | 2026-04-29T07:28:32.507Z |
| Last seen | 2026-04-29T07:28:32.507Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | UHSVJfdgkQlN |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Dr. Reddy’s Laboratories has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection. Sun Pharma, Dr. Reddy’s, Zydus, Glenmark roll out generic SemaglutideIt has become the first company to receive the market authorisation for generic Semaglutide Injection in Canada, ahead of Health Canada’s review target date. The authorisation covers the 2 mg/pen (1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).Canada is recognised as the world’s second-largest market for Semaglutide, Dr. Reddy’s said, citing IQVIA MAT Q3 2025 numbers. Dr. Reddy’s biologics unit gets U.S. FDA queriesWith launch preparations under way, it is well-positioned to bring the “important treatment option available to Canadian patients”.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu — Top.
Discussion
0 commentsMore from The Hindu — Top
